Overview |
bs-0097R-APC |
ALK Polyclonal Antibody, APC Conjugated |
FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
Human |
Mouse, Rat, Dog, Cow, Horse |
Specifications |
APC |
Rabbit |
KLH conjugated synthetic peptide derived from human CD246 |
329-342/1620 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
238 |
Cell membrane |
ALK tyrosine kinase receptor; ALK tyrosine kinase receptor precursor; ALK/EML4 fusion gene, included; ALK/NPM1 fusion gene, included; anaplastic lymphoma kinase Ki-1; Anaplastic lymphoma kinase; Anaplastic lymphoma kinase Ki 1; Anaplastic lymphoma kinase Ki1; Anaplastic lymphoma kinase p80; CD 246; CD246; CD-246; CD246 antigen; EC 2.7.10.1; Ki 1; Ki1; NBLST3; Tcrz; TFG/ALK. |
This gene encodes a receptor tyrosine kinase, which belongs to the insulin receptor superfamily. This protein comprises an extracellular domain, an hydrophobic stretch corresponding to a single pass transmembrane region, and an intracellular kinase domain. It plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system. This gene has been found to be rearranged, mutated, or amplified in a series of tumours including anaplastic large cell lymphomas, neuroblastoma, and non-small cell lung cancer. The chromosomal rearrangements are the most common genetic alterations in this gene, which result in creation of multiple fusion genes in tumourigenesis, including ALK (chromosome 2)/EML4 (chromosome 2), ALK/RANBP2 (chromosome 2), ALK/ATIC (chromosome 2), ALK/TFG (chromosome 3), ALK/NPM1 (chromosome 5), ALK/SQSTM1 (chromosome 5), LK/KIF5B (chromosome 10), ALK/CLTC (chromosome 17), ALK/TPM4 (chromosome 19), and ALK/MSN (chromosome X).[provided by RefSeq, Jan 2011]. |
Application Dilution |
FCM |
1:20-100 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |